Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma × pexidartinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Gastrointestinal Stromal Tumors 2 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Recurrence 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Gemcitabine 12 Doxorubicin 11 pembrolizumab 10 Radiotherapy 10 Nivolumab 7 Docetaxel 7 Cyclophosphamide 6 pazopanib 5 Filgrastim 5 Imatinib Mesylate 4 Ifosfamide 4 130-nm albumin-bound paclitaxel 4 eribulin 3 Vinorelbine 3 Temozolomide 3 Sirolimus 3 PM 01183 3 Irinotecan 3 Ipilimumab 3 Drug Therapy 3 Cisplatin 3 Albumin-Bound Paclitaxel 3 talimogene laherparepvec 2 surufatinib 2 selinexor 2 repotrectinib 2 poly ICLC 2 pegfilgrastim 2 liposomal doxorubicin 2 avelumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡